New Blood Biomarkers for Gastric Cancer Treatment
Author Information
Author(s): Piccinno Emanuele, Schirizzi Annalisa, Scalavino Viviana, De Leonardis Giampiero, Donghia Rossella, Fantasia Alessia, Ricci Angela Dalia, Lotesoriere Claudio, Giannelli Gianluigi, Serino Grazia, D’Alessandro Rosalba, Felekkis Kyriacos N., Papaneophytou Christos
Primary Institution: National Institute of Gastroenterology, IRCCS “S. de Bellis” Research Hospital
Hypothesis
Can circulating miRNAs predict therapy outcomes in advanced gastric cancer patients receiving Ramucirumab and Paclitaxel?
Conclusion
The study suggests that miR-23b-3p, miR-30e-3p, and miR-205-5p may serve as non-invasive predictive markers for therapy outcomes in advanced gastric cancer.
Supporting Evidence
- Circulating levels of miR-205-5p were found to have a protective effect on overall survival.
- Patients with higher baseline levels of miR-205-5p had longer overall survival compared to those with lower levels.
- Three miRNAs were identified as potential biomarkers for predicting therapy outcomes.
Takeaway
Doctors can use certain tiny molecules in the blood to help figure out how well a treatment for stomach cancer is working.
Methodology
The study analyzed blood samples from 40 patients undergoing second-line therapy with Ramucirumab and Paclitaxel, focusing on the expression levels of specific circulating miRNAs.
Potential Biases
Potential biases may arise from the selection of patients and the retrospective nature of the study.
Limitations
The study is retrospective and may not account for all variables affecting patient outcomes.
Participant Demographics
Patients were adults with advanced gastric cancer, with a median age of approximately 67 years.
Statistical Information
P-Value
0.02
Confidence Interval
0.16 to 0.86
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website